经胸心脏超声引导射频消融房室结加VVI起搏11例

目的评价在心内射频消融中应用经胸二维超声心动图（TTE）作为影像学引导电极导管到位的可行性、安全性、有效性。方法10例持续性、永久性房颤患者和1例房扑患者以TTE作为影像学指导电极导管置放、靶点标测。结果TTE对10例患者成功引导了房室结阻断术并植入心脏永久起搏器,对1例患者成功实现了房扑消融。结论TTE可成功作为影像学指导,部分或全部替代X线透视引导心内射频消融术。     

心房颤动房室结消融及永久起搏器治疗长期疗效观察

观察永久性心房颤动（房颤）伴快速心室率患者行房室结消融及永久起搏器治疗后长期疗效及病死率。     

房室结消融加永久起搏器植入治疗老年药物抵抗性心房颤动

心房颤动治疗方法有药物治疗、房室结消融并植入永久起搏器治疗、肺静脉电隔离术治疗等。本文总结4例老年药物抵抗性心房纤颤患者行房室结导管射频消融术并VVIR型起搏器植入术临床资料,探讨其安全性和有效性。1对象和方法1.1对象2002年10月~2005年2月老年药物抵抗心房纤颤患者4(男2、女2)例。年龄75~81岁,左房前后径47.8~56.6 mm,右室流出道内径24.6~25.5 mm,左室射血分数59%~73%。1.2方法1.2.1房室结消融4 mm大弯温控消融导管,记录到希氏束电位,60℃试消融,出现快速交界心律后继续消融至出现缓慢规律心室率,再巩固消融60 s。1.2.2 VVIR…     

老年心房颤动不同方式的经导管射频消融治疗

目的研究不同方式经导管射频消融治疗对老年房颤的治疗效果。方法53例房颤患者，男性38例，女性15例，年龄60-83岁。按接受不同的经导管消融方法将上述患者分为3组：消融隔离肺静脉治疗阵发性房颤组20例、消融典型房扑治疗房颤合并房扑组26例、消融房室传导加植入永久性起搏器治疗持续性房颤伴药物难以控制的快速心室率和（或）心力衰竭组7例。结果消融隔离肺静脉组中15例采用环状标测电极导管引导电隔离3～4根肺静脉成功，术后无房颤发作8例（53％），房颤发作明显减少4例（27％）；采用电解剖系统引导下环双侧肺静脉线性消融隔离肺静脉5例，无房颤发作4例（80％）。消融房扑组26例典型房扑均消融成功，随访中15例（58％）无房颤发作，8例（31％）房颤发作较前减少。经导管消融房室传导组7例全部成功，4例行右心室、3例行双心室VVI模式起搏，随访中生活质量和（或）心力衰竭症状明显改善。结论针对不同类型的老年房颤患者采用不同的经导管消融方法可以取得较好的临床效果。     

双瓣置换术后持续心房扑动行房室结改良并安置起搏器一例

患者男性 ,5 2岁 ,1983年行二尖瓣闭式分离术。 1999年行二尖瓣及主动脉瓣置换术。 1年多后行心房扑动 (简称房扑 )射频消融术及起搏器安置 ,术中直接消融房扑折返的最狭窄部位 ,但未能终止房扑的发作 ,改行房室结慢径消融成功 ,并安装VVIR起搏器痊愈出院。房扑消融失败原因考虑与两次心脏手术后 ,根据解剖影像确定的线性切割消融方法的靶点难以把握所致     

射频消融房室交界区和植入起搏器治疗心房颤动

目的 对9例阵发性心房颤动(房颤)和8例慢性房颤患者行房室交界区消融和植入起搏器(Abl+Pm)治疗,探讨这一方法的临床治疗效果。方法 经右股静脉植入4极电极导管于右心室心尖部和4极大头消融导管至房室交界区,于记录到希氏束电位处放电消融,直至出现三度房室阻滞,然后植入VVI或DDD起搏器。结果 所有患者均成功阻断房室交界区并植入起搏器。8例慢性房颤患者植入VVI起搏器,术后血流动力学稳定、临床症状改善,3个月后心胸比例由原来的0.62±0.04缩小为0.57±0.05,差异有显著性(P<0.05),心功能(NYHA分级)均提高Ⅰ级以上;9例阵发性房颤患者中,8例植入VVI起搏器,1例植入DDD起搏器,房颤发作时,8例无临床症状,1例仅有轻微心悸。随访1～47个月,无1例出现起搏器综合征、栓塞和心功能恶化。结论 房颤患者的Abl+Pm治疗可有效控制临床症状、改善心功能和提高生活质量。     

射频消融治疗心律失常的现状和进展(续)

(接上期 ) (四 )心房颤动的射频消融房颤的人群发生率为 0 .15 %～ 1% ,6 5岁以上者发生率达 5 .9% ,是临床上最常见的心律失常 ,主要以心悸不适、心输出量下降、诱发和加重心功能不全及血栓栓塞为主要危害。房颤的治疗包括减慢房颤时的心室率和房颤的根治治疗。应用导管消融房室结和希氏束 ,术后植入永久起搏器对有些病例尤其是老年患者仍较适用。对于房室结慢径改良以控制心室率的问题 ,由于不同临床研究报导的成功率变异度较大 (15 %～ 92 % ) ,且有一定比例的患者有发生Ⅲ度房室传导阻滞的危险 ,因此选择该方法治疗时仍应慎重对待 ,近年…     

经导管消融治疗心房颤动的现状与展望

经导管消融治疗心房颤动(atrial fibrillation，房颤)一直是电生理领域的研究热点。上世纪90年代，经历了房室结改良术控制心室率、毁损房室结造成三度房室阻滞加起搏器植入、仿迷宫术线性消融、肺静脉内点消融、环形消融等多种术式，本世纪初，则以节段性肺静脉电隔离术、三维电解剖标测系统指导下环肺静脉口消融术为主。     

峡部依赖性心房扑动对心房颤动发作的影响

目的观察导管射频消融治疗峡部依赖性心房扑动(房扑)对心房颤动(房颤)发作的影响,进一步探讨房扑和房颤的关系。方法86例房扑患者,其体表心电图均提示典型房扑,男性54例、女性32例,年龄50.0±15.6(11～74)岁,病程5.6±6.4(0.1～30)年。将所有患者分成A、B两组,A组为房扑合并房颤患者,共25例;B组为不合并房颤患者,共61例;其中A组同时合并房室结折返性心动过速(AVNRT)3例,房室折返性心动过速(AVRT)4例,阵发性房性心动过速(PAT)10例;B组合并房室结折返性心动过速5例,房室折返性心动过速7例。对峡部依赖性房扑者,线性消融下腔静脉—三尖瓣环峡部致双向传导阻滞;房室折返性心动过速者行旁道消融术;房室结折返性心动过速者行慢径改良术,阵发性房速术中持续或可诱发,予以射频消融。平均随访27.1±14.1(6～63)月。结果A组25例患者中,术后68%(17/25)患者不再发作房颤;其余8例仍有房颤发作,其中1例为术前同时合并房室折返性心动过速,5例为合并阵发性房速。61例术前不合并房颤者,术后随访中有16.4%(10/61)新发房颤。86例患者中,6例因病态窦房结综合征行起搏器植入术,随访未诉心悸、胸闷,心电图为窦性心律与起搏心律交替出现。结论房扑可能与房颤具有共同的发生基质,也可以是房颤的触发因素,成功消融房扑后可以阻止房颤的发生。但房颤发生机制多样,消融峡部依赖性房扑,仍会发生房颤,术前合并房颤或房速者是最强的预测因子。     

预激综合征合并完全性房室阻滞的诊断及治疗

目的 报道5例预激综合征合并完全性房室阻滞患者的诊断和治疗。方法 进行心内电生理检查和射频消融旁路。结果 电生理检查未诱发房室折返性心动过速，心房刺激时体表心电图的预激程度无变化。消融阻断旁路前传后，均示完全性房室阻滞。4例患者在消融术后植入永久性起搏器．随访中无心房颤动发作。1例患者放弃对旁路的消融治疗。结论 预激综合征合并完全性房室阻滞是射频消融的适应证。消融前对房室传导功能的评定十分重要。成功消融旁路后应植入永久性起搏器。     

Predictors of atrial rhythm after atrioventricular node ablation for the treatment of paroxysmal atrial arrhythmias

OBJECTIVE: To assess the natural history of the atrial rhythm of patients with paroxysmal atrial arrhythmias undergoing atrioventricular node ablation and permanent pacemaker implantation. DESIGN AND SETTING: A retrospective cohort study of consecutive patients identified from the pacemaker database and electrophysiology records of a tertiary referral hospital. PATIENTS: 62 consecutive patients with paroxysmal atrial arrhythmias undergoing atrioventricular node ablation and permanent pacemaker implantation between 1988 and July 1996. MAIN OUTCOME MEASURES: (1) Atrial rhythm on final follow up ECG, classified as either ordered (sinus rhythm or atrial pacing) or disordered (atrial fibrillation, atrial flutter or atrial tachycardia). (2) Chronic atrial fibrillation, defined as a disordered rhythm on two consecutive ECGs (or throughout a 24 hour Holter recording) with no ordered rhythm subsequently documented. RESULTS: Survival analysis showed that 75% of patients progressed to chronic atrial fibrillation by 2584 days (86 months). On multiple logistic regression analysis a history of electrical cardioversion, increasing patient age, and VVI pacing were associated with the development of chronic atrial fibrillation. A history of electrical cardioversion and increasing patient age were associated with a disordered atrial rhythm on the final follow up ECG. CONCLUSIONS: Patients with paroxysmal atrial arrhythmias are at high risk of developing chronic atrial fibrillation. A history of direct current cardioversion.     

Cholesterol lowering and coronary artery disease: mechanisms of risk reduction

OBJECTIVE: To assess the effect of atrioventricular node ablation and implantation of a dual chamber, mode switching pacemaker on quality of life, exercise capacity, and left ventricular systolic function in patients with drug refractory paroxysmal atrial fibrillation. PATIENTS: 18 consecutive patients with drug refractory paroxysmal atrial fibrillation. METHODS: Quality of life was assessed before and after the procedure using the psychological general wellbeing index (PGWB), the McMaster health index (MHI), and a visual analogue scale for cardiac symptoms. Nine of the patients also underwent symptom limited exercise tests and echocardiography to assess left ventricular systolic function. RESULTS: The procedure allowed a reduction in antiarrhythmic drug treatment (p < 0.01). PGWB and symptom scores improved (p < 0.01) but the MHI score did not change. Left ventricular systolic function and exercise capacity were unchanged. CONCLUSIONS: Atrioventricular node ablation and implantation of a DDDR/MS pacemaker is effective treatment for refractory paroxysmal atrial fibrillation, producing improved quality of life while allowing a reduction in drug burden. The popularity of the treatment is justified, but further studies are needed to determine optimum timing of intervention.     

Treatment of refractory recurrent multifocal atrial tachycardia with atrioventricular junction ablation and permanent pacing

Multifocal atrial tachycardia is a difficult clinical problem generally associated with acute cardiorespiratory illness. The purpose of this study was to assess the feasibility and clinical utility of atrioventricular junction ablation plus permanent transvenous pacemaker implantation as therapy for uncontrolled refractory multifocal atrial tachycardia. Three patients with uncontrolled refractory multifocal atrial tachycardia underwent atrioventricular junction ablation plus permanent transvenous pacemaker implantation. Complications and outcome of each procedure was monitored and both objective and subjective assessment of physical functional capacity was assessed by a semiquantitative examination. Ablation procedures controlled the ventricular response in all patients. There were no complications related to the ablation procedure or implantation of permanent transvenous pacing system. All patients demonstrated subjective improvement in symptoms. Palpitations were virtually eradicated in these patients and all enjoyed significant improvements in rest and effort dyspnea, exercise tolerance and asthenia. Objective assessment of functional class also demonstrated significant improvements. Atrioventricular ablation plus permanent transvenous pacing offers a safe and effective therapy for uncontrolled refractory multifocal atrial tachycardia.     

Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation

OBJECTIVES: We evaluated the incidence and predictors of sudden death after atrioventricular (AV) node ablation and pacemaker implantation. BACKGROUND: Sudden death may occur after radiofrequency catheter ablation of the AV node and pacemaker implantation in patients with atrial fibrillation (AF). Whether it is related to the procedure or to pre-existing heart disease remains unclear. METHODS: All patients who had radiofrequency catheter ablation of the AV node and pacemaker implantation for rate control of medically refractory AF were identified retrospectively and observed prospectively. All patients with sudden death after ablation were identified. The relationship between the procedure and sudden death was defined on the basis of the time between the two as "likely," "possibly" or "unlikely." RESULTS: Of 334 consecutive patients with AF who underwent AV node ablation, nine had sudden death after the ablation. Four patients (1.2%) had sudden death likely related to the procedure: in 3 patients, arrest occurred within 48 h after the procedure; in one patient, arrest occurred four days after the procedure. In three other patients (0.9%), sudden death was possibly related to the procedure because the event occurred within three months afterward. The remaining two deaths were unrelated to the procedure. Diabetes, New York Heart Association functional class (>or=II), preprocedure ventricular arrhythmia, mitral or aortic stenosis, aortic regurgitation and chronic obstructive pulmonary disease were independent predictors for sudden death. CONCLUSIONS: Sudden death likely or possibly related to catheter ablation occurred in 7 of 334 patients (2.1%). Risk of sudden death is highest within two days after the procedure.     

超声引导下实施射频消融房室结安置VVI起搏器初步探讨

探索经胸心脏超声引导心内射频消融房室结的可行性和安全性。对11例持续/永久性心房颤动/心房扑动拟行房室结消融加VVI起搏,在经胸心脏彩超引导下,采取多切面观察、导管运动中观察,密切结合心内电生理定位,尝试左锁骨下静脉永久起搏导管和右股静脉消融导管的心内定位和靶点消融。以出现稳定的房室分离判为消融成功。结果:11例房室结消融及VVI起搏均顺利完成,手术时间70～180min,放电期间超声切面可见能量释放征,消融后靶点区心内膜回声明显增强。手术成功率100%,随访期内患者恢复良好。结论:经胸切面超声引导射频消融房室结安置VVI起搏安全、简便、可行、经济。     

射频消融阻断房室交界区术后早期室性快速性心律失常及猝死的预防

心室率控制是房颤治疗的一种有效手段,而房室交界区消融加永久起搏器植入术是治疗药物难治性房颤的一项成熟技术,但是在房室交界区消融术后早期可发生室性快速性心律失常及猝死。现就其发生机制和预防措施作一综述。     

Atrioventricular nodal ablation and biventricular pacing therapy with coronary venoplasty for severe heart failure with drug refractory atrial tachycardia

A 53-year-old man was admitted to our hospital for dyspnea, associated with atrial tachycardia. He underwent mitral valve replacement and Maze operation for mitral regurgitation and atrial fibrillation and since then he suffered from drug refractory atrial tachycardia followed by cardiogenic shock with systolic heart failure. Atrial tachycardia with rapid ventricular response was medically refractory, and radical catheter ablation was thought to be very difficult due to post Maze operation, mitral mechanical valve replacement and unstable hemodynamics. Thus, atrioventricular nodal ablation, which was s safe procedure compared to the radical ablation for this patient, and biventricular pacemaker implantation, which required coronary venoplasty, were performed. Combination therapy may be one of the treatments for heart failure patients with drug refractory tachyarrhythmias.     

Long-term results of the corridor operation for atrial fibrillation.

OBJECTIVE--To investigate the long-term results of the corridor operation in the treatment of symptomatic atrial fibrillation refractory to drug treatment. BACKGROUND--The corridor operation is designed to isolate from the left and right atrium a conduit of atrial tissue connecting the sinus node area with the atrioventricular node region in order to preserve physiological ventricular drive. The excluded atria can fibrillate without affecting the ventricular rhythm. This surgical method offers an alternative treatment when atrial fibrillation becomes refractory to drug treatment. PATIENTS--From 1987 to 1993, 36 patients with drug refractory symptomatic paroxysmal atrial fibrillation underwent surgery. The in hospital rhythm was followed thereafter by continuous rhythm monitoring and with epicardial electrograms. After discharge Holter recording and stress testing were regularly carried out to evaluate the sinus node function and to detect arrhythmias; whereas Doppler echocardiography was used to measure atrial contraction and size. MAIN OUTCOME MEASURES--Maintained absence of atrial fibrillation without drug treatment after operation; preservation of normal chronotropic response in the sinus node. RESULTS--The corridor procedure was successful in 31 (86%) of the 36 patients. After a mean (SD) follow up of 41 (16) months 25 (69%) of the 36 patients were free of arrhythmias without taking drugs (mean (SE) actuarial freedom at four years 72 (9)%)). Paroxysmal atrial fibrillation recurred in three patients; paroxysmal atrial flutter (two patients) and atrial tachycardia (one patient) developed in the corridor in three others. Among the 31 patients in whom the operation was successful sinus node function at rest and during exercise remained undisturbed in 26 and 25 patients respectively (mean (SE) actuarial freedom of sinus node dysfunction at four years (81(7)%)). Pacemakers were needed in five (16%) of the 31 patients for insufficient sinus node rhythm at rest only. Doppler echocardiography showed maintenance of right atrial contribution to right ventricle filling in 26 of the 31 patients after operation in contrast to the left atrium, which never showed such contribution. His bundle ablation was performed and a pacemaker implanted in the five patients in whom the corridor operation was unsuccessful. CONCLUSION--These results substantiate the idea of this surgical procedure. Modification of the technique is, however, needed to achieve a reliable isolation between left atrium and corridor, which would make this experimental surgery widely applicable in the treatment of drug refractory atrial fibrillation.     

Remodeling of sinus node function after catheter ablation of right atrial flutter

INTRODUCTION: The purpose of this study was to investigate the effect of ablation of right atrial flutter upon sinus node function in humans. METHODS AND RESULTS: This study enrolled 35 patients. Twenty-four patients (16 men and 8 women; age 68 +/- 11 years) were referred for ablation of persistent atrial flutter (duration 8 +/- 11 months). After ablation, there was abnormal sinus node function defined as a corrected sinus node recovery time (CSNRT) > or = 550 msec. The control group consisted of 11 patients who were undergoing pacemaker implantation for sinus node disease but did not have a history of atrial dysrhythmias or ablation. Within 24 hours of ablation or pacemaker implantation, baseline maximal CSNRT was measured through a permanent pacemaker by AAI pacing at six cycle lengths: 600, 550, 500, 450, 400, and 350 msec. CSNRT then was measured in the same manner at 48 hours, 14 days, and 3 months after ablation/pacemaker implantation. P wave amplitude and duration, and percent atrial sensing also were assessed at the same intervals. For patients undergoing atrial flutter ablation, there was progressive temporal recovery of CSNRT (1,204 +/- 671 msec at baseline vs 834 +/- 380 msec at 3 months; P < 0.001) and a significant increase in the percent atrial sensing and P wave amplitude at 3 months compared with baseline (P < 0.001). In control subjects, there was no change in the CSNRT, percent atrial pacing, or P wave amplitude. CONCLUSION: After ablation of persistent atrial flutter, there is temporal recovery of CSNRT and increase in spontaneous atrial activity. These findings suggest that atrial flutter induces reversible changes in sinus node function.